SCHEMBL4486950

SCHEMBL4486950

O=C(CN1CCCC1)Nc1cccc(C(=O)NCCN2CCC(OC(=O)N(c3ccccc3-c3ccccc3)c3ccccc3-c3ccccc3)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.46
HPGD P15428 1/20 0.45
ATR Q13535 2/20 0.45
SMYD2 Q9NRG4 1/20 0.43
POLB P06746 1/20 0.42
CHRM3 P20309 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
DRD4 P21917 1/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
HTR7 P34969 2/20 0.41
HTR1A P08908 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
ALDH1A1 P00352 2/20 0.41
APP P05067 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480540 0.95 EPHX2 (0.45) EPHX2ATRCHRM3MEN1KMT2A
SCHEMBL4477851 0.93 ALDH1A1 (0.51) EPHX2POLBCHRM3ALDH1A1
SCHEMBL4486948 0.93 EPHX2 (0.44) EPHX2HPGDATRSMYD2POLB
SCHEMBL4470444 0.90 CARM1 (0.48) EPHX2CHRM3CARM1PRMT6HTR7
SCHEMBL265175 0.89 CHRM3 (0.56) CHRM3
SCHEMBL4494146 0.89 EPHX2 (0.46) EPHX2CHRM3CARM1PRMT6HTR7
SCHEMBL4478408 0.88 EPHX2 (0.45) EPHX2CHRM3CARM1PRMT6HTR7
SCHEMBL4482920 0.88 CHRM3 (0.45) EPHX2CHRM3CARM1PRMT6HTR7
SCHEMBL4482357 0.88 EPHX2 (0.45) EPHX2ATRCHRM3CARM1PRMT6
SCHEMBL4480537 0.87 EPHX2 (0.43) EPHX2ATRCHRM3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632847-B2 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester THERAVANCE, INC. (US) 2009-12-15 US disclosed